Improvement in progressive multifocal leukoencephalopathy after pembrolizumab‐induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma

Inès Dufour; Thierry Duprez; Marie Wertz; Pascale Saussoy; Nathalie Ackermans; Souraya El Sankari; Vincent van Pesch; Eric Van Den Neste

doi:10.1002/jha2.56

eJHaem (Nov 2020)

Improvement in progressive multifocal leukoencephalopathy after pembrolizumab‐induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma

Inès Dufour,
Thierry Duprez,
Marie Wertz,
Pascale Saussoy,
Nathalie Ackermans,
Souraya El Sankari,
Vincent van Pesch,
Eric Van Den Neste

Affiliations

Inès Dufour: Department of Hematology Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Thierry Duprez: Department of Radiology and Medical Imaging Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Marie Wertz: Department of Neurology Clinique Notre‐Dame de Grâce Gosselies Belgium
Pascale Saussoy: Hematology Laboratory Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Nathalie Ackermans: Department of Neurology Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Souraya El Sankari: Department of Neurology Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Vincent van Pesch: Department of Neurology Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium
Eric Van Den Neste: Department of Hematology Université catholique de Louvain, Cliniques universitaires Saint‐Luc Brussels Belgium

DOI: https://doi.org/10.1002/jha2.56
Journal volume & issue: Vol. 1, no. 2
pp. 585 – 588

Abstract

Read online

Abstract Progressive multifocal leukoencephalopathy (PML) may develop in follicular lymphoma patients treated with bendamustine‐rituximab. In this report, treatment with pembrolizumab successfully inhibited the clinical progression of PML by promoting radiologically demonstrated immune restoration inflammatory syndrome (IRIS), allowing complete clearance of the virus. These findings may further support the use of pembrolizumab in PML with special consideration for the potential occurrence of IRIS.

Published in eJHaem

ISSN: 2688-6146 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: https://onlinelibrary.wiley.com/journal/26886146

About the journal

Abstract

Keywords